Milestone Pharma reports Q3 2023 results; NDA submitted for etripamil in PSVT

Milestone Pharmaceuticals Inc.

2023-Q3 EPS reported -$1.07

Cash $75.7M as of Sep 30, 2023; expected to fund operations into mid-2025.
Q3 operating loss $15.4M vs $15.0M prior year; R&D expense down to $6.7M.
NDA for etripamil (CARDAMYST) in PSVT submitted to FDA; acceptance decision by end of 2023.
Positive Phase 2 ReVeRA data for etripamil in AFib-RVR presented at AHA; Phase 3 program to start mid-2024.
Commercial expense rose to $4.4M in Q3 from $2.7M prior year, building pre-launch capabilities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Milestone Pharmaceuticals Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023, which also provided a clinical and corporate update.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-116646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.